NCT04407078 is a NA clinical trial of Sugammadex Injectable Product in Gallbladder Diseases, sponsored by Ajou University School of Medicine.

Who is sponsoring NCT04407078?

NCT04407078 is sponsored by Ajou University School of Medicine.

What drugs are being tested in NCT04407078?

Interventions in NCT04407078: Sugammadex Injectable Product, Neostigmine Injectable Product.

What condition does NCT04407078 study?

NCT04407078 studies Gallbladder Diseases.

Is NCT04407078 still recruiting?

NCT04407078 is currently completed. Last updated 8 January 2021.

Last reviewed 2021-01-08 · How we verify

NCT04407078

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female

Completed NA Last updated 8 January 2021

What this trial tests

NA trial testing Sugammadex Injectable Product in Gallbladder Diseases in 40 participants. Completed in 6 January 2021.

Timeline

2 December 2019

Primary endpoint
6 January 2021

6 January 2021

Quick facts

Lead sponsor	Ajou University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	40
Start date	2 December 2019
Primary completion	6 January 2021
Estimated completion	6 January 2021
Sites	1 location across South Korea

Drugs / interventions tested

Sugammadex Injectable Product — full drug profile →
Neostigmine Injectable Product — full drug profile →

Conditions studied

Gallbladder Diseases — all drugs for Gallbladder Diseases →

Sponsor

Ajou University School of Medicine

Who can join

Adults 19 to 60, female only, with Gallbladder Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female who are reversed with sugammadex or neostigmine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sugammadex Injectable Product

Trials testing the same drug.

NCT03583021 — Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Male · NA · completed

Other Ajou University School of Medicine trials

Trials by the same sponsor.

NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
NCT05751603 — Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex · NA · not yet recruiting
NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04407078 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
Last refreshed: 8 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04407078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing